305 related articles for article (PubMed ID: 18053228)
21. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
22. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins.
Andrews TC; Ballantyne CM; Hsia JA; Kramer JH
Am J Med; 2001 Aug; 111(3):185-91. PubMed ID: 11530028
[TBL] [Abstract][Full Text] [Related]
23. Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia.
Athyros VG; Papageorgiou AA; Athyrou VV; Demitriadis DS; Pehlivanidis AN; Kontopoulos AG
J Cardiovasc Risk; 2002 Feb; 9(1):33-9. PubMed ID: 11984215
[TBL] [Abstract][Full Text] [Related]
24. Implications of a defined daily dose fixed database for drug utilization research studies: The case of statins in Portugal.
Abrantes C; Tonin FS; Reis-Pardal J; Castel-Branco M; Furtado C; Figueiredo IV; Fernandez-Llimos F
Br J Clin Pharmacol; 2021 Sep; 87(9):3542-3549. PubMed ID: 33576512
[TBL] [Abstract][Full Text] [Related]
25. A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels.
Wilson K; Marriott J; Fuller S; Lacey L; Gillen D
Pharmacoeconomics; 2003; 21 Suppl 1():1-11. PubMed ID: 12648030
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect.
Zhou Z; Rahme E; Abrahamowicz M; Tu JV; Eisenberg MJ; Humphries K; Austin PC; Pilote L
CMAJ; 2005 Apr; 172(9):1187-94. PubMed ID: 15851712
[TBL] [Abstract][Full Text] [Related]
27. Opioid prescribing habits differ between Denmark, Sweden and Norway - and they change over time.
Jarlbaek L
Scand J Pain; 2019 Jul; 19(3):491-499. PubMed ID: 30817310
[TBL] [Abstract][Full Text] [Related]
28. Lipid treatment goals achieved in patients treated with statin drugs in Norwegian general practice.
Svilaas A; Risberg K; Thoresen M; Ose L
Am J Cardiol; 2000 Dec; 86(11):1250-3, A6. PubMed ID: 11090801
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
Jones PH; Davidson MH; Stein EA; Bays HE; McKenney JM; Miller E; Cain VA; Blasetto JW;
Am J Cardiol; 2003 Jul; 92(2):152-60. PubMed ID: 12860216
[TBL] [Abstract][Full Text] [Related]
30. Statins reduce new-onset atrial fibrillation in a first-time myocardial infarction population: a nationwide propensity score-matched study.
Bang CN; Gislason GH; Greve AM; Torp-Pedersen C; Køber L; Wachtell K
Eur J Prev Cardiol; 2014 Mar; 21(3):330-8. PubMed ID: 23012689
[TBL] [Abstract][Full Text] [Related]
31. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
Smith DG; McBurney CR
Pharmacoeconomics; 2003; 21 Suppl 1():13-23. PubMed ID: 12648031
[TBL] [Abstract][Full Text] [Related]
32. Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease.
Perreault S; Blais L; Dragomir A; Bouchard MH; Lalonde L; Laurier C; Collin J
Eur J Clin Pharmacol; 2005 Oct; 61(9):667-74. PubMed ID: 16151763
[TBL] [Abstract][Full Text] [Related]
33. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland.
Bennie M; Godman B; Bishop I; Campbell S
Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):125-30. PubMed ID: 22280202
[TBL] [Abstract][Full Text] [Related]
34. A 10-Year Trend in Statin Use Among Older Adults in Australia: an Analysis Using National Pharmacy Claims Data.
Ofori-Asenso R; Ilomäki J; Zomer E; Curtis AJ; Zoungas S; Liew D
Cardiovasc Drugs Ther; 2018 Jun; 32(3):265-272. PubMed ID: 29790056
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.
Costa-Scharplatz M; Ramanathan K; Frial T; Beamer B; Gandhi S
Clin Ther; 2008 Jul; 30(7):1345-57. PubMed ID: 18691996
[TBL] [Abstract][Full Text] [Related]
36. Impact of the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22/Reversal of Atherosclerosis with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada.
Austin PC; Mamdani MM
Circulation; 2005 Aug; 112(9):1296-300. PubMed ID: 16116054
[TBL] [Abstract][Full Text] [Related]
37. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy.
Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
Pharmacoepidemiol Drug Saf; 2010 Jan; 19(1):75-81. PubMed ID: 19802823
[TBL] [Abstract][Full Text] [Related]
38. Gender differences in statin prescription rates, adequacy of dosing, and association of statin therapy with outcome after heart failure hospitalization: a retrospective analysis in a community setting.
Ballo P; Balzi D; Barchielli A; Turco L; Franconi F; Zuppiroli A
Eur J Clin Pharmacol; 2016 Mar; 72(3):311-9. PubMed ID: 26581760
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the prescription and utilization patterns of statins in an Italian local health unit during the period 1994-2003.
Deambrosis P; Saramin C; Terrazzani G; Scaldaferri L; Debetto P; Giusti P; Chinellato A
Eur J Clin Pharmacol; 2007 Feb; 63(2):197-203. PubMed ID: 17200832
[TBL] [Abstract][Full Text] [Related]
40. Trends in statin prescription prevalence, initiation, and dosing: Hong Kong, 2004-2015.
Blais JE; Chan EW; Law SWY; Mok MT; Huang D; Wong ICK; Siu CW
Atherosclerosis; 2019 Jan; 280():174-182. PubMed ID: 30529830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
